Molecular pathways: Digoxin use and estrogen-sensitive cancers - Risks and possible therapeutic implications

Clinical Cancer Research

Volumn 18, Issue 8, 2012, Pages 2133-2137

  Biggar, Robert J ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; DIGITALIS; DIGOXIN; ESTROGEN; ESTROGEN RECEPTOR; NEUROLEPTIC AGENT; SPIRONOLACTONE;

BREAST CANCER; CANCER INCIDENCE; CANCER RISK; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG USE; GALACTORRHEA; GYNECOMASTIA; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; UTERUS CANCER;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DIGOXIN; ESTROGENS; FEMALE; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PHYTOESTROGENS; RECEPTORS, ESTROGEN; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SPIRONOLACTONE; TAMOXIFEN; UTERINE NEOPLASMS;

EID: 84859863854     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1389     Document Type: Review

References (60)

1. Ahern TP, Lash TL, Sørensen HT, Petersen L. Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case control study. Breast Cancer Res 2008;10:R102.
2. Biggar RJ, Wohlfahrt J, Oudin A, Hjuler T. Mads Melbye. Digoxin use and the risk of breast cancer in women. J Clin Oncol 2011;29: 2165-70.
3. Biggar RJ, Wohlfahrt J, Melbye M. Digitalis and the risk of cancers of the corpus uteri, ovary and cervix. Int J Cancer 2011 Sep 12. [Epub ahead of print].
4. McDonough AA, Velotta JB, Schwinger RH, Philipson KD, Farley RA. The cardiac sodium pump: structure and function. Basic Res Cardiol 2002;97(suppl 1):I19-24.
5. Rifka SM, Pita JC Jr, Loriaux DL. Mechanism of interaction of digitalis with estradiol binding sites in rat uteri. Endocrinology 1976;99: 1091-6.
6. Rifka SM, Pita JC, Vigersky RA, Wilson YA, Loriaux DL. Interaction of digitalis and spironolactone with human sex steroid receptors. J Clin Endocrinol Metab 1978;46:338-44. (Pubitemid 8312337)
7. Dickey RP, Stone SC. Drugs that affect the breast and lactation. Clin Obstet Gynecol 1975;18:95-111.
8. Braustein GD. Gynecomastia. N Engl J Med 1993;328:490-5.
9. Colditz GA, Baer HJ, Tamimi RM. Breast cancer. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention. New York: Oxford University Press, Inc.; 2006. p. 995-1012.
10. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Martin L, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009;360:573-87.
11. Dietel M. Hormone replacement therapy (HRT), breast cancer and tumor pathology. Maturitas 2010;65:183-9.
12. Furness S, Roberts H, Marjoribanks J, Lethaby A, Hickey M, Farquhar C. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2009; CD000402.
13. Pike MC, Ross RK. Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids 2000;65: 659-64.
14. Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS. Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007;16:2548-56. (Pubitemid 351196308)
15. Beral V, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007;369: 1703-10. (Pubitemid 46755369)
16. Lacey JV Jr, Brinton LA, Leitzmann MF, Mouw T, Hollenbeck A, Schatzkin A, et al. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst 2006;98:1397-405. (Pubitemid 44530716)
17. Gadducci A, Barsotti C, Cosio S, Domenici L, Riccardo Genazzani A. Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. Gynecol Endocrinol 2011;27:597-604.
18. Stenkvist B, Pengtsson E, Dahlqvist B, Eriksson O, Jarkrans T, Nordin B. Cardiac glycosides and breast cancer, revisited. N Engl J Med 1982;306:484. (Pubitemid 12171682)
19. Friedman GD. Digitalis and breast cancer. Lancet 1984;324:875. (Pubitemid 14015502)
20. Haux J, Klepp O, Spigset O, Tretli S. Digitoxin medication and cancer; case control and internal dose-response studies. BMC Cancer 2001;1:11.
21. Lenfant-Pejovic MH, Mlika-Cabanne N, Bouchardy C, Auquier A. Risk factors for male breast cancer: a Franco-Swiss case-control study. Int J Cancer 1990;45:661-5. (Pubitemid 20146125)
22. Ewertz M, Holmberg L, Tretli S, Pedersen BV, Kristensen A. Risk factors for male breast cancer-a case-control study from Scandinavia. Acta Oncol 2001;40:467-71. (Pubitemid 32682030)
23. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997;44:445-8. (Pubitemid 27382061)
24. Tinelli A, Vergara D, Martignago R, Leo G, Malvasi A, Tinelli R. Hormonal carcinogenesis and socio-biological development factors in endometrial cancer: a clinical review. Acta Obstet Gynecol Scand 2008;87:1101-13.
25. Platz EA, Yegnasubramanian S, Liu JO, Chong CR, Shim JS, Kenfield SA, et al.Anovel two-stage transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov 2011;1:69-77.
26. Horisberger JD, Giebisch G. Potassium-sparing diuretics. Ren Physiol 1987;10:198-220.
27. Barbato JC. Estrogen receptor activation-good, aldosterone receptor blockade-beneficial, communication between receptors. . .priceless. Hypertension 2007;50:297-8. (Pubitemid 47205776)
28. Satoh T, Munakata H, Fujita K, Itoh S, Kamataki T, Yoshizawa I. Studies on the interactions between drug and estrogen. II. On the inhibitory effect of 29 drugs reported to induce gynecomastia on the oxidation of estradiol at C-2 or C-17. Biol Pharm Bull 2003;26:695-700. (Pubitemid 39663566)
29. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987;60:820-5. (Pubitemid 17163442)
30. Haynes BA, Mookadam F. Male gynecomastia. Mayo Clin Proc 2009;84:672.
31. Jick H, Armstrong B. Letter: Breast cancer and spironolactone. Lancet 1975;306:368-9.
32. Loube SD, Quirk RA. Letter: Breast cancer associated with administration of spironolactone. Lancet 1975;305:1428-9.
33. Lamy O, Elmiger H, Fiche M, Bauer J, Livio F. Acquired hemophilia as first manifestation of breast carcinoma in a man under long-term spironolactone therapy. Int J Clin Oncol 2004;9:130-3. (Pubitemid 38619328)
34. Stierer M, Spoula H, Rosen HR. [Breast cancer in the male-a retrospective analysis of 15 cases] Onkologie 1990;13:128-31 [German].
35. Danielson DA, Jick H, Hunter JR, Stergachis A, Madsen S. Nonestrogenic drugs and breast cancer. Am J Epidemiol 1982;116:329-32. (Pubitemid 12048412)
36. Horwitz RI, Feinstein AR. Exclusion bias and the false relationship of reserpine and breast cancer. Arch Intern Med 1985;145:1873-5. (Pubitemid 16221744)
37. Grossman E, Messerli FH, Goldbourt U. Carcinogenicity of antihypertensive therapy. Curr Hypertens Rep 2002;4:195-201.
38. Dalton SO, Johansen C, Poulsen AH, Nørgaard M, Sørensen HT, McLaughlin JK, et al. Cancer risk among users of neuroleptic medication: a population-based cohort study. Br J Cancer 2006;95: 934-9. (Pubitemid 44498111)
39. Galbraith RA, Michnovicz JJ. The effects of cimetidine on the oxidative metabolism of estradiol. N Engl J Med 1989;321:269-74. (Pubitemid 19193800)
40. García Rodríguez LA, Jick H. Risk of gynaecomastia associated with cimetidine, omeprazole, and other antiulcer drugs. BMJ 1994;308: 503-6.
41. Rossing MA, Scholes D, Cushing-Haugen KL, Voigt LF. Cimetidine use and risk of prostate and breast cancer. Cancer Epidemiol Biomarkers Prev 2000;9:319-23. (Pubitemid 30165445)
42. Habel LA, Levin TR, Friedman GD. Cimetidine use and risk of breast, prostate, and other cancers. Pharmacoepidemiol Drug Saf 2000;9: 149-55. (Pubitemid 30307357)
43. Tempfer CB, Froese G, Heinze G, Bentz EK, Hefler LA, Huber JC. Side effects of phytoestrogens: a meta-analysis of randomized trials. Am J Med 2009;122:939-46.e9.
44. This P, de Cremoux P, Leclercq G, Jacquot Y. A critical view of the effects of phytoestrogens on hot flashes and breast cancer risk. Maturitas 2011;70:222-6.
45. Bandera EV, Williams MG, Sima C, Bayuga S, Pulick K, Wilcox H, et al. Phytoestrogen consumption and endometrial cancer risk: a population- based case-control study in New Jersey. Cancer Causes Control 2009;20:1117-27.
46. Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry-history, content, quality, and use. Dan Med Bull 1997;44: 535-9.
47. Brennan ME, Houssami N. Overview of long term care of breast cancer survivors. Maturitas 2011;69:106-12.
48. Maclennan AH. HRT in difficult circumstances: are there any absolute contraindications? Climacteric 2011;14:409-17.
49. Norman SA, Weber AL, Localio AR, Marchbanks PA, Ursin G, Strom BL, et al. Hormone therapy and fatal breast cancer. Pharmacoepidemiol Drug Saf 2010;19:440-7.
50. Chen W, Petitti D, Geiger A. Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: a computer record-linkage study. Br J Cancer 2005;93:392-8. (Pubitemid 43080011)
51. Rivera-Guevara C, Camacho J. Tamoxifen and its new derivatives in cancer research. Recent Patents Anticancer Drug Discov 2011;6: 237-45.
52. Pinkerton JV, Goldstein SR. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. Menopause 2010;17:642-53.
53. Williams-Brown MY, Salih SM, Xu X, Veenstra TD, Saeed M, Theiler SK, et al. The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk. J Steroid Biochem Mol Biol 2011;126: 78-86.
54. Chumsri S, Howes T, Bao T, Sabnis G, Brodie A. Aromatase, aromatase inhibitors, and breast cancer. J Steroid Biochem Mol Biol 2011;125:13-22.
55. Stenkvist B. Is digitalis a therapy for breast carcinoma? Oncol Rep 1999;6:493-6.
56. Haux J. Digitoxin is a potential anticancer agent for several types of cancer. Med Hypotheses 1999;53:543-8. (Pubitemid 30064132)
57. Kometiani P, Liu L, Askari A. Digitalis-induced signaling by Na+/ K+-ATPase in human breast cancer cells. Mol Pharmacol 2005;67: 929-36. (Pubitemid 40365340)
58. Winnicka K, Bielawski K, Bielawska A. Synthesis and cytotoxic activity of G3 PAMAM-NH(2) dendrimer-modified digoxin and proscillaridin A conjugates in breast cancer cells. Pharmacol Rep 2010; 62:414-23.
59. Johansson S, Lindholm P, Gullbo J, Larsson R, Bohlin L, Claeson P. Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells. Anticancer Drugs 2001;12:475-83. (Pubitemid 32643092)
60. Reddel RR, Sutherland RL. Effects of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro. Cancer Res 1987;47:5323-9. (Pubitemid 17152940)